Primary source: Wolters Kluwer press release, November 13, 2026. The page's structured data carries a publish time of 12:00 UTC that day.
On November 13, 2026, Wolters Kluwer Health signed an agreement to acquire AgileMD for up to $100 million. Forty million dollars is paid upfront. The rest is deferred and depends on performance targets the release does not list. AgileMD's products, Pathways and eCART, run inside the EHR, where the clinical note is written. The release does not mention CDI, coding, claims, or denials. The deal has not closed.
Dividing those figures by the company's expected $7 million of ARR at year-end 2026 gives about 5.7 times and about 14.3 times. Those ratios are RevCycleAI's arithmetic on company-stated figures. The $7 million is an expectation, not a reported trailing number. The release prints no multiple.
Wolters Kluwer's release says the company has signed an agreement. It does not say the acquisition has closed. Closing is expected in the first quarter of 2027 or sooner, subject to customary closing conditions and other governmental approvals.
| Item | What the release states |
|---|---|
| Buyer | Wolters Kluwer Health. The About section says Wolters Kluwer, Euronext: WKL, reported 2025 revenue of €6.1 billion and employs about 21,100 people. The same release says this acquisition is expected to have an immaterial impact on adjusted earnings. RevCycleAI's company page still describes the firm through MediRegs and compliance research. This announcement is a different product. |
| Target | AgileMD, San Francisco, founded in 2011. Co-founders Borna Safabakhsh, chief executive, and Dana Edelson, M.D., chief medical officer. All 23 employees will join Wolters Kluwer Health. |
| Price | Up to $100 million, of which $40 million is an upfront payment. The balance is deferred consideration contingent on reaching certain performance targets. The release does not print the deferred piece as its own number. $100 million minus $40 million is $60 million. That subtraction is RevCycleAI's. The release does not say which targets, or what share of the balance is earned if only some of them are hit. |
| ARR and return | AgileMD "is expected to reach" annual recurring revenue of $7 million by year-end 2026. That is the company's expectation. The acquisition is expected to achieve a return on invested capital at or above Wolters Kluwer's after-tax weighted average cost of capital of 8%, within 3 to 5 years. |
| Products | AI-powered clinical decision support: interactive clinical pathways and predictive analytics, described as a way to make care more consistent and to help reduce mortality. Pathways operationalizes local guidelines in the EHR workflow, for consistency and outcomes measurement. eCART is a real-time AI-powered clinical surveillance engine that the release calls FDA-cleared, with a footnote marker, and that is "designed to help reduce mortality rates." The release does not print the footnote text on the page. |
| UpToDate | Since its introduction in September 2025, UpToDate Expert AI has been adopted by more than 2,700 U.S. hospitals and health systems, representing more than 95% of U.S.-based UpToDate Enterprise Edition customers. Those figures are the company's. |
"Combined with UpToDate Expert AI and our partnerships, AgileMD will serve as a vital enabler for true UpToDate ubiquity in healthcare – facilitating UpToDate's expansion into embedded workflows, local guidelines, and new digital health applications," said Yaw Fellin, Senior Vice President, Wolters Kluwer Clinical Solutions. "With AgileMD, we are well positioned to help healthcare systems provide better patient care and extract more value from their tech investments."
"We are excited to join Wolters Kluwer Health. Coupled with UpToDate, AgileMD can more fully deliver its transformative impact in critical decision support workflows. Leveraging UpToDate's foundational capabilities, AgileMD will accelerate and streamline the development and maintenance of more advanced clinical pathways for complex clinical decision-making support." — Borna Safabakhsh, co-founder and chief executive of AgileMD.
Fellin names embedded workflows, local guidelines, and new digital health applications. Safabakhsh names clinical pathways for complex decision support. Neither quotation mentions a claim, a code, a denial, or a clinical documentation improvement query.
$40 million divided by $7 million is 5.714, which rounds to 5.7. $100 million divided by $7 million is 14.286, which rounds to 14.3. The denominator is expected ARR by the end of 2026, not revenue Wolters Kluwer says AgileMD has already booked. A 5.7 times figure on an expectation is not a 5.7 times figure on a trailing year. The ceiling multiple uses the full $100 million, which is only paid if the performance targets are met, and those targets are not in the release. Use 5.7 as the upfront check against the company's own ARR expectation. Use 14.3 only as the ceiling against that same expectation.
This is clinical decision support, not a revenue-cycle company and not a coding company. The release does not mention CDI, coding, claims, or denials. It does not say eCART or Pathways writes a charge, appeals a denial, or checks medical necessity for a payer. It has not closed. An immaterial impact on adjusted earnings is the buyer's own description of the size.
This is RevCycleAI's read. The revenue-cycle interest in this deal is not that Wolters Kluwer bought a billing tool. It did not, on this page. The interest is where the product sits. Pathways "operationalizes local guidelines in the EHR workflow." That is the same workflow in which the clinician's note is created, and the note is what clinical documentation improvement, medical-necessity review, and a later denial defense have to work from. If the guideline is in the chart at the moment of documentation, the downstream argument about whether the record supports the service starts from a different document than a pathway that lives in a separate library.
Fellin's line is the strategy sentence. UpToDate Expert AI, already in more than 2,700 U.S. hospitals and health systems by the company's count, is the distribution. AgileMD is how that content gets into local guidelines and embedded workflows, rather than staying a reference someone opens beside the chart. Safabakhsh says the combination speeds the building and upkeep of more advanced pathways. That is a content and workflow claim. It is not a yield claim. Nothing in the release says documentation queries fell, denial rates moved, or case mix changed.
The check size tells you how the buyer is filing it. Up to $100 million, against a company expected to be at $7 million of ARR, inside a group with €6.1 billion of 2025 revenue, with an immaterial effect on adjusted earnings and a return hurdle of an 8% after-tax cost of capital over three to five years. This is a tuck-in under UpToDate. It is not a bet the size of a revenue-cycle platform. Suki's Series E, covered here in October, is the earlier place UpToDate Expert AI showed up in a clinical workflow, through Suki's Ask feature. That was a partnership inside a documentation product. This is Wolters Kluwer buying the pathway layer itself. Different structure. Same neighborhood of the chart. Still not a claim.
Wolters Kluwer signed, and has not closed, to put AgileMD's EHR pathways under UpToDate for up to $100 million, $40 million of it upfront. On the company's expected $7 million ARR, that is about 5.7 times upfront and about 14.3 times at the ceiling. Those are RevCycleAI's ratios. The release does not mention CDI, coding, claims, or denials. The close is expected in the first quarter of 2027, if the conditions are met.
File it under the note, then stop. A revenue-cycle leader can care that local guidelines are being embedded where documentation is created, because that is the record CDI and denial defense inherit. The release does not say AgileMD does that work, and it does not give a result that would let you price it as denial prevention. Forty million dollars is the cash that does not depend on a target the company kept to itself. The other $60 million, which is our subtraction, waits on targets the release does not print. The open item is the close, expected in the first quarter of 2027 or sooner, and still ahead.
What the product does, what the release leaves out, and the multiple labeled as arithmetic.
Sources: Wolters Kluwer, "Wolters Kluwer to acquire AI-powered clinical decision support platform AgileMD," November 13, 2026 (page opened; structured data datePublished 2026-11-13T12:00:00+00:00). The signed agreement, the up-to-$100-million price, the $40 million upfront payment, the contingent deferred balance, AgileMD's founding year, city, co-founders, and 23 employees, the $7 million expected ARR, the ROIC and 8% after-tax WACC language, the immaterial adjusted-earnings impact, the first-quarter 2027 close expectation, Pathways, eCART as FDA-cleared in the release's wording, the UpToDate Expert AI adoption figures, the €6.1 billion and about 21,100 people in the About section, and the quotations from Yaw Fellin and Borna Safabakhsh are the release's. Both quotations are verbatim. The 5.7 times and 14.3 times ratios, and the $60 million remainder, are RevCycleAI's arithmetic on those company figures. The release does not mention CDI, coding, claims, or denials, and this article does not add them. The deal had not closed as of the release.